122 related articles for article (PubMed ID: 28497874)
1. Serum angiopoietin-2 level as a potential biomarker in psoriasis vulgaris.
Takahashi T; Asano Y; Shibata S; Tada Y; Sato S
J Dermatol; 2017 Feb; 44(2):205-206. PubMed ID: 28497874
[No Abstract] [Full Text] [Related]
2. Leucine-rich α-2 glycoprotein is an innovative biomarker for psoriasis.
Nakajima H; Serada S; Fujimoto M; Naka T; Sano S
J Dermatol Sci; 2017 May; 86(2):170-174. PubMed ID: 28179066
[No Abstract] [Full Text] [Related]
3. Marked decrease in serum squamous cell carcinoma antigen level after antitumor necrosis factor alpha therapy in six cases of severe psoriasis.
Iriki H; Tanese K; Furuichi Y; Takeshita K; Saito M
Int J Dermatol; 2016 Jun; 55(6):e364-6. PubMed ID: 26696364
[No Abstract] [Full Text] [Related]
4. Serum fatty acid-binding protein 4 level is inversely correlated with serum thymus and activation-regulated chemokine level in psoriatic patients achieving clear skin by biologics.
Honma M; Shibuya T; Iinuma S; Ishida-Yamamoto A
J Dermatol; 2019 Apr; 46(4):e116-e117. PubMed ID: 30216494
[No Abstract] [Full Text] [Related]
5. Serum YKL-40 as a potential biomarker of inflammation in psoriasis.
Baran A; Myśliwiec H; Szterling-Jaworowska M; Kiluk P; Świderska M; Flisiak I
J Dermatolog Treat; 2018 Feb; 29(1):19-23. PubMed ID: 28498006
[TBL] [Abstract][Full Text] [Related]
6. Liver fatty acid-binding protein might be a predictive marker of clinical response to systemic treatment in psoriasis.
Baran A; Kiluk P; Maciaszek M; Świderska M; Flisiak I
Arch Dermatol Res; 2019 Jul; 311(5):389-397. PubMed ID: 30993401
[TBL] [Abstract][Full Text] [Related]
7. Effect of psoriasis activity and topical treatment on serum lipocalin-2 levels.
Baran A; Świderska M; Myśliwiec H; Flisiak I
J Dermatolog Treat; 2017 Mar; 28(2):136-140. PubMed ID: 27165470
[TBL] [Abstract][Full Text] [Related]
8. Increased MicroRNA-1266 levels as a biomarker for disease activity in psoriasis vulgaris.
Seifeldin NS; El Sayed SB; Asaad MK
Int J Dermatol; 2016 Nov; 55(11):1242-1247. PubMed ID: 27371164
[TBL] [Abstract][Full Text] [Related]
9. Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: Results of a pilot study.
Gkalpakiotis S; Arenbergerova M; Gkalpakioti P; Potockova J; Arenberger P; Kraml P
J Dermatol; 2017 Apr; 44(4):363-369. PubMed ID: 27774694
[TBL] [Abstract][Full Text] [Related]
10. Psoriasis therapy and cardiovascular risk factors: a 12-week follow-up study.
Coimbra S; Oliveira H; Reis F; Belo L; Rocha S; Quintanilha A; Figueiredo A; Teixeira F; Castro E; Rocha-Pereira P; Santos-Silva A
Am J Clin Dermatol; 2010 Dec; 11(6):423-32. PubMed ID: 20429617
[TBL] [Abstract][Full Text] [Related]
11. Serum prolactin levels in psoriasis and correlation with cutaneous disease activity.
Dilmé-Carreras E; Martín-Ezquerra G; Sánchez-Regaña M; Umbert-Millet P
Clin Exp Dermatol; 2011 Jan; 36(1):29-32. PubMed ID: 20608944
[TBL] [Abstract][Full Text] [Related]
12. The effect of topical treatment and psoriasis severity on serum retinol-binding protein-4 levels.
Baran A; Swiderska M; Flisiak I
J Dermatolog Treat; 2016; 27(2):114-9. PubMed ID: 26293108
[TBL] [Abstract][Full Text] [Related]
13. Serum irisin levels in patients with psoriasis.
Baran A; Myśliwiec H; Kiluk P; Świderska M; Flisiak I
J Dermatolog Treat; 2017 Jun; 28(4):304-308. PubMed ID: 27786588
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of transforming growth factor-beta1 in patients with mild psoriasis vulgaris and effect of treatment with biological drugs.
Kallimanis PG; Xenos K; Markantonis SL; Stavropoulos P; Margaroni G; Katsambas A; Avgerinou G
Clin Exp Dermatol; 2009 Jul; 34(5):582-6. PubMed ID: 19094132
[TBL] [Abstract][Full Text] [Related]
15. In-depth serum proteomics reveals biomarkers of psoriasis severity and response to traditional Chinese medicine.
Xu M; Deng J; Xu K; Zhu T; Han L; Yan Y; Yao D; Deng H; Wang D; Sun Y; Chang C; Zhang X; Dai J; Yue L; Zhang Q; Cai X; Zhu Y; Duan H; Liu Y; Li D; Zhu Y; Radstake TRDJ; Balak DMW; Xu D; Guo T; Lu C; Yu X
Theranostics; 2019; 9(9):2475-2488. PubMed ID: 31131048
[TBL] [Abstract][Full Text] [Related]
16. Soluble Receptor for Advanced Glycation End Products: A Novel Biomarker for Psoriasis Severity with Therapeutic Implications?
Batycka-Baran A; Baran W; Nowicka-Suszko D; Szepietowski JC
Acta Derm Venereol; 2018 Aug; 98(8):797-798. PubMed ID: 29963680
[No Abstract] [Full Text] [Related]
17. Safety of ustekinumab in severe psoriasis with chronic hepatitis B.
Raymundo AR; Facin AP; Silva de Castro CC; Faria AR
Indian J Dermatol Venereol Leprol; 2016; 82(3):326-8. PubMed ID: 27088944
[No Abstract] [Full Text] [Related]
18. First experience with therapy of severe forms of psoriasis with biosimilar infliximab.
Tichy M; Kopova R; Sternbersky J
J Eur Acad Dermatol Venereol; 2016 Mar; 30(3):491-3. PubMed ID: 25418715
[No Abstract] [Full Text] [Related]
19. Serum interleukin-6 levels in response to biologic treatment in patients with psoriasis.
Muramatsu S; Kubo R; Nishida E; Morita A
Mod Rheumatol; 2017 Jan; 27(1):137-141. PubMed ID: 27194220
[TBL] [Abstract][Full Text] [Related]
20. Estimation of tissue and serum lipocalin-2 in psoriasis vulgaris and its relation to metabolic syndrome.
El-Hadidi H; Samir N; Shaker OG; Otb S
Arch Dermatol Res; 2014 Apr; 306(3):239-45. PubMed ID: 24052155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
